Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving dasatinib 100mg once daily

被引：0
|
作者：
Le Coutre, P. [1 ]
Shah, N. [2 ]
Cortes, J. E. [3 ]
Schiffer, C. [4 ]
Bahceci, E. [5 ]
Lambert, A. [6 ]
Saglio, G. [7 ]
机构：
[1] Charite Campus Virchow Klinikum, Berlin, Germany
[2] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Commun, San Francisco, CA USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Hudson Webber Canc Res Ctr, Detroit, MI USA
[5] Bristol Myers Squibb Co, Plainsboro, NJ USA
[6] Bristol Myers Squibb Co, Braine Lalleud, Belgium
[7] Osped San Luigi Gonzaga, Div Med Interna & Ematol, Lab Med & Oncol Mol, Turin, Italy
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：82 / 82
页数：1
相关论文
共 50 条
  • [41] Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
    Shah, Neil P.
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Rea, Delphine
    Dorlhiac-Llacer, Pedro E.
    Milone, Jorge H.
    Vela-Ojeda, Jorge
    Silver, Richard T.
    Khoury, H. Jean
    Charbonnier, Aude
    Khoroshko, Nina
    Paquette, Ronald L.
    Deininger, Michael
    Collins, Robert H.
    Otero, Irma
    Hughes, Timothy
    Bleickardt, Eric
    Strauss, Lewis
    Francis, Stephen
    Hochhaus, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (19) : 3204 - 3212
  • [42] Opportunistic Infections Are Uncommon with Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
    Al-Ameri, Ali
    Kantarjian, Hagop
    Borthakur, Gautam
    Bahceci, Erkut
    Szatrowski, Ted
    Damokosh, Andrew
    Cortes, Jorge
    BLOOD, 2009, 114 (22) : 459 - 459
  • [43] Molecular Responses to Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Michor, Franziska
    Olshen, Adam
    Gonen, Mithat
    Jones, Dan
    Rios, Mary Beth
    O'Brien, Susan
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 1114 - 1115
  • [44] Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up
    Shah, Neil
    Kantarjian, Hagop
    Hochhaus, Andreas
    Cortes, Jorge E.
    Bradley-Garelik, M. Brigid
    Zhu, Chao
    Baccarani, Michele
    BLOOD, 2010, 116 (21) : 94 - 94
  • [45] Dasatinib vs imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): DASISION European subpopulation analysis
    Stegelmann, F.
    Mayer, J.
    Warzocha, K.
    Huguet, F.
    Steegmann, J. L.
    Gambacorti-Passerini, C.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    ONKOLOGIE, 2012, 35 : 47 - 48
  • [46] Predictors of Long-Term Cytogenetic Response Following Dasatinib Therapy of Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
    Jabbour, Elias
    Bahceci, Erkut
    Zhu, Chao
    Lambert, Alexandre
    Cortes, Jorge
    BLOOD, 2009, 114 (22) : 1278 - 1278
  • [47] Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group.
    Cervantes, Francisco
    Lopez-Garrido, Pilar
    Montero, Maria-Isabel
    Jonte, Femin
    Martinez, Jesus
    Hernan-dez-Boluda, Juan-Carlos
    Calbacho, Maria
    Sureda, Anna
    Perez-Rus, Gloria
    Nieto, Jose
    Perez-Lopez, Cristina
    Roman, Jose
    Gonzalez, Marcos
    Pereira, Arturo
    Colomer, Dolors
    BLOOD, 2009, 114 (22) : 456 - 457
  • [48] SURVIVAL OUTCOMES IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING THIRD-OR SUBSEQUENT LINE (3L) TREATMENT PRIOR TO THE AVAILABILITY OF PONATINIB
    Stellato, D.
    McGarry, L.
    Huang, H.
    Hastings, S.
    Delea, T.
    HAEMATOLOGICA, 2017, 102 : 434 - 434
  • [49] Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
    Kantarjian, Hagop M.
    Shah, Neil P.
    Cortes, Jorge E.
    Baccarani, Michele
    Agarwal, Mohan B.
    Soledad Undurraga, Maria
    Wang, Jianxiang
    Kassack Ipina, Juan Julio
    Kim, Dong-Wook
    Ogura, Michinori
    Pavlovsky, Carolina
    Junghanss, Christian
    Milone, Jorge H.
    Nicolini, Franck E.
    Robak, Tadeusz
    Van Droogenbroeck, Jan
    Vellenga, Edo
    Bradley-Garelik, M. Brigid
    Zhu, Chao
    Hochhaus, Andreas
    BLOOD, 2012, 119 (05) : 1123 - 1129
  • [50] Impact of Treatment Strategies on Clinical Outcomes In Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients In Canada
    Cribb, Nancy
    Merali, Tazmin
    Donato, Bonnie M. K.
    BLOOD, 2010, 116 (21) : 1063 - 1063
12345